| 2.56 -0.02 (-0.78%) | 11-07 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |   |
|||
| Targets | 6-month : | 3.79 | 1-year : | 4.43 |
| Resists | First : | 3.25 | Second : | 3.79 |
| Pivot price | 2.5  |
|||
| Supports | First : | 2.27 | Second : | 1.67 |
| MAs | MA(5) : | 2.71 |
MA(20) : | 2.32 |
| MA(100) : | 1.71 |
MA(250) : | 2.78 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.2 |
| %K %D | K(14,3) : | 57.8 |
D(3) : | 64.1 |
| RSI | RSI(14): 58.1 |
|||
| 52-week | High : | 14.09 | Low : | 0.61 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ NMRA ] has closed below upper band by 46.5%. Bollinger Bands are 121.9% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 10 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 2.65 - 2.68 | 2.68 - 2.69 |
| Low: | 2.35 - 2.38 | 2.38 - 2.4 |
| Close: | 2.52 - 2.58 | 2.58 - 2.61 |
Neumora Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in developing therapeutic treatments for brain diseases, neuropsychiatric disorders, and neurodegenerative diseases. The company develops navacaprant (NMRA-140), a novel once-daily oral kappa opioid receptor antagonist, which is in phase 3 clinical trials for the treatment of major depressive disorder. It also develops NMRA-511 that is in phase 1 clinical trials in patients with agitation associated with dementia due to Alzheimer's disease; and NMRA-266, which is in the phase 1 clinical trial for the treatment of schizophrenia and other neuropsychiatric disorders. In addition, its preclinical phase product includes NMRA-NMDA for the treatment of schizophrenia; NMRA-CK1d, a CK1d inhibitor program for the treatment of amyotrophic lateral sclerosis; NMRA-NLRP3 for the treatment of certain neurodegenerative conditions; and NMRA-GCase for the treatment of Parkinson's disease. The company was formerly known as RBNC Therapeutics, Inc. and changed its name to Neumora Therapeutics, Inc. in October 2021. Neumora Therapeutics, Inc. was incorporated in 2019 and is headquartered in Watertown, Massachusetts.
Thu, 30 Oct 2025
Needham Lifts PT on Neumora Therapeutics (NMRA) to $8 From $6, Keeps a Buy Rating - Insider Monkey
Thu, 30 Oct 2025
Neumora Therapeutics (NASDAQ:NMRA) Director Kristina Burow Acquires 1,915,700 Shares - MarketBeat
Wed, 20 Aug 2025
Neumora Therapeutics Initiates Phase 1 Study for Schizophrenia Drug NMRA-861 - Insider Monkey
Mon, 07 Apr 2025
Neumora Therapeutics, Inc. Investors: Please contact the - GlobeNewswire
Wed, 02 Apr 2025
Lost Money on Neumora Therapeutics, Inc. (NMRA)? Join Class Actio - The National Law Review
Wed, 02 Apr 2025
NMRA Stock Price and Chart — NASDAQ:NMRA - TradingView
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 162 (M) |
| Shares Float | 86 (M) |
| Held by Insiders | 27.5 (%) |
| Held by Institutions | 53.6 (%) |
| Shares Short | 6,790 (K) |
| Shares Short P.Month | 6,420 (K) |
| EPS | -1.58 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 1.12 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -52.7 % |
| Return on Equity (ttm) | -89.4 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.64 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -196 (M) |
| Levered Free Cash Flow | -106 (M) |
| PE Ratio | -1.64 |
| PEG Ratio | 0 |
| Price to Book value | 2.26 |
| Price to Sales | 0 |
| Price to Cash Flow | -2.12 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|